We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

48 hedge funds and large institutions have $15.1M invested in Matinas BioPharma in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

7% more funds holding

Funds holding: 45 → 48 (+3)

0.01% more ownership

Funds ownership: 0.23% → 0.25% (+0.01%)

16% less capital invested

Capital invested by funds: $18M → $15.1M (-$2.9M)

Holders
48
Holders Change
+3
Holders Change %
+6.67%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
17
Reduced
9
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AWMG
Alliance Wealth Management Group
New Jersey
+$535K
2
State Street
State Street
Massachusetts
+$301K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$252K
4
Northern Trust
Northern Trust
Illinois
+$89.6K
5
Morgan Stanley
Morgan Stanley
New York
+$78.6K

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$161K
2
Millennium Management
Millennium Management
New York
-$86K
3
BCM
Bridgeway Capital Management
Texas
-$81.4K
4
Citadel Advisors
Citadel Advisors
Florida
-$61K
5
UBS Group
UBS Group
Switzerland
-$43.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
SG Americas Securities
26
SG Americas Securities
New York
$54K +$55.1K +825 New
Creative Planning
27
Creative Planning
Kansas
$49K – – –
State of Wisconsin Investment Board
28
State of Wisconsin Investment Board
Wisconsin
$48K – – –
AIG
29
American International Group
New York
$47K +$3.54K +53 +8%
CS
30
Credit Suisse
Switzerland
$46K +$31K +464 +204%
VOYA Investment Management
31
VOYA Investment Management
Georgia
$44K – – –
JMPWA
32
JP Morgan Private Wealth Advisors
California
$40K +$40K +600 New
NFA
33
Nationwide Fund Advisors
Ohio
$39K – – –
Goldman Sachs
34
Goldman Sachs
New York
$26K +$12.1K +182 +83%
AllianceBernstein
35
AllianceBernstein
Tennessee
$22K – – –
SO
36
STRS Ohio
Ohio
$20K – – –
AQR Capital Management
37
AQR Capital Management
Connecticut
$19K +$19.3K +289 New
TSS
38
Two Sigma Securities
New York
$16K -$11K -165 -40%
Commonwealth Equity Services
39
Commonwealth Equity Services
Massachusetts
$13K – – –
Legal & General Group
40
Legal & General Group
United Kingdom
$10K – – –
UBS Group
41
UBS Group
Switzerland
$9K -$43.6K -653 -84%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$6.8K -$534 -8 -7%
AIP
43
Ameritas Investment Partners
Nebraska
$5K – – –
Wells Fargo
44
Wells Fargo
California
$5K +$4.94K +74 New
Bank of America
45
Bank of America
North Carolina
$3K +$3.6K +54 New
Barclays
46
Barclays
United Kingdom
$2K +$1.53K +23 +2,300%
MAM
47
Meeder Asset Management
Ohio
$2K +$1.53K +23 +177%
Millennium Management
48
Millennium Management
New York
– -$86K -1,015 Closed
Citadel Advisors
49
Citadel Advisors
Florida
– -$61K -722 Closed
TRCT
50
Tower Research Capital (TRC)
New York
– -$17.7K -265 Closed
1
2
3

MTNB Hedge Fund Activity: Q3 2017 in Review

48 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2017, worth a combined $15.1M — down 16% from $18M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MTNB positions and 3 closed out — a net gain of 4 holders — while 17 added to existing stakes and 9 trimmed.

The largest buyer was Alliance Wealth Management Group, adding an estimated $535K. The largest seller was Royal Bank of Canada, cutting an estimated $161K.

  • 48 institutional investors held Matinas BioPharma (MTNB) as of Q3 2017, up from 45 in Q2 2017.
  • Funds reported $15.1M of Matinas BioPharma stock for Q3 2017, down 16% quarter-over-quarter.
  • 7 funds opened new Matinas BioPharma positions in Q3 2017 and 3 closed out, a net change of +4 holders.
  • The largest Matinas BioPharma buyer in Q3 2017 was Alliance Wealth Management Group, an estimated $535K added.
  • The largest Matinas BioPharma seller in Q3 2017 was Royal Bank of Canada, an estimated $161K sold.

Based on aggregated 13F filings for Q3 2017.